AMAG AMAG Pharmaceuticals Inc.

15.51
+0.2  (+1%)
Previous Close 15.31
Open 15.36
Price To Book 0.72
Market Cap 536750848
Shares 34,606,760
Volume 386,175
Short Ratio
Av. Daily Volume 590,003

NewsSee all news

  1. AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference
  2. Edited Transcript of AMAG earnings conference call or presentation 7-Feb-19 1:00pm GMT
  3. AMAG Pharmaceuticals (AMAG) Q4 2018 Earnings Conference Call Transcript
  4. AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
  5. AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Misses Revenue Estimates

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 19611472
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607676
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604977
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 19593420
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 19590321

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data due 1H 2020.
Digoxin immune fab (DIF)
Severe preeclampsia in pregnant women
PDUFA date extended to June 23, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Approval for sNDA filing announced February 5, 2018.
Feraheme
Adults with iron deficiency anemia (IDA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference
  2. Edited Transcript of AMAG earnings conference call or presentation 7-Feb-19 1:00pm GMT
  3. AMAG Pharmaceuticals (AMAG) Q4 2018 Earnings Conference Call Transcript
  4. AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
  5. AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Misses Revenue Estimates
  6. AMAG Pharmaceuticals: 4Q Earnings Snapshot
  7. AMAG Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
  8. AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 7, 2019 at 8:00 a.m. ET
  9. AMAG Pharmaceuticals Completes Acquisition of Perosphere Pharmaceuticals
  10. Research Report Identifies Edison International, MPLX LP, Moody's, AMAG Pharmaceuticals, Cross Country Healthcare, and New Mountain Finance with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  11. AMAG Pharmaceuticals Appoints Christine Moulton Clemson, Ph.D., M.S.C.I. as Vice President of Medical Affairs
  12. AMAG Pharmaceuticals Announces Preliminary 2018 Financial Results and Provides 2019 Financial Guidance
  13. Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
  14. Spectrum Pharmaceuticals: Financial Overview in December
  15. AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
  16. AMAG Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
  17. AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
  18. AMAG Pharmaceuticals Enters Into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals
  19. Estimating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
  20. Study of Feraheme demonstrates Improvements in Fatigue and Quality Of Life in Iron Deficiency Anemia Patients

SEC Filings

  1. CT ORDER - Confidential treatment order 19611472
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607676
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604977
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 19593420
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 19590321
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19581780
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19579638
  8. 8-K - Current report 19573425
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19539426
  10. 8-K - Current report 19530087